<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[NOVO — April 2025]]></title><description><![CDATA[<p dir="auto">Novo: Kursfald avler forventninger om yderligere kursfald <a href="https://proinvestor.com/boards/125494" rel="nofollow ugc">https://proinvestor.com/boards/125494</a></p>
]]></description><link>https://dev.proinvestor.com/forum/topic/400320/novo-april-2025</link><generator>RSS for Node</generator><lastBuildDate>Sat, 06 Jun 2026 07:32:56 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/400320.rss" rel="self" type="application/rss+xml"/><pubDate>Tue, 01 Apr 2025 04:15:14 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to NOVO — April 2025 on Wed, 30 Apr 2025 14:57:44 GMT]]></title><description><![CDATA[<p dir="auto">Regnskabssæsonen er fuld i gang, Novo Nordisk laver aftale med kopisælgere, og USA er kommet med nye tal, der giver indblik i den første måned med de nye toldsatser fra Donald Trump. Hør også om regnskaber fra DSV, Apple, Amazon, Eli Lilly og meget mere i afsnit 272 af Investeringspodcasten. <a href="https://proinvestor.com/boards/126122/" rel="nofollow ugc">https://proinvestor.com/boards/126122/</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985347</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985347</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 30 Apr 2025 14:57:44 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Wed, 30 Apr 2025 06:06:33 GMT]]></title><description><![CDATA[<p dir="auto">Novo får sænket kursmålet hos Danske Bank: Spørgsmålene hober sig op <a href="https://proinvestor.com/investornyt/1310051/novo-far-saenket-kursmalet-hos-danske-bank-sporgsmalene-hober-sig-op" rel="nofollow ugc">https://proinvestor.com/investornyt/1310051/novo-far-saenket-kursmalet-hos-danske-bank-sporgsmalene-hober-sig-op</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985349</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985349</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 30 Apr 2025 06:06:33 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Wed, 30 Apr 2025 03:22:07 GMT]]></title><description><![CDATA[<p dir="auto">How Will Eli Lilly Stock React To Its Upcoming Earnings? <a href="https://proinvestor.com/investornyt/1309961/how-will-eli-lilly-stock-react-to-its-upcoming-earnings" rel="nofollow ugc">https://proinvestor.com/investornyt/1309961/how-will-eli-lilly-stock-react-to-its-upcoming-earnings</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985346</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985346</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 30 Apr 2025 03:22:07 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Wed, 30 Apr 2025 03:06:18 GMT]]></title><description><![CDATA[<p dir="auto">Novo Nordisk investorer holder øje med Eli Lilly regnskab <a href="https://proinvestor.com/boards/126107" rel="nofollow ugc">https://proinvestor.com/boards/126107</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985348</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985348</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 30 Apr 2025 03:06:18 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 12:16:38 GMT]]></title><description><![CDATA[<p dir="auto">Forhåbentligt kan Novo vinde nogle markedsandele gennem DTC. Det er hårdt tiltrængt</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985343</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985343</guid><dc:creator><![CDATA[lahn1]]></dc:creator><pubDate>Tue, 29 Apr 2025 12:16:38 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 12:15:44 GMT]]></title><description><![CDATA[<p dir="auto">Nemlig Bikube. Ved at sælge direkte f.eks via HIMS eller Novocare cutter de PBM's ud af liningen og kan derved sælge langt billigere end via apotekerne. Et super signal til administrationen. Med PBM's via apotekerne $1200/md eller $499 på Novocare / $599 via Teledocs.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985342</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985342</guid><dc:creator><![CDATA[lahn1]]></dc:creator><pubDate>Tue, 29 Apr 2025 12:15:44 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 11:27:00 GMT]]></title><description><![CDATA[<p dir="auto">Novos aftale med teleapotek ses som godt nyt - aktien stiger <a href="https://proinvestor.com/investornyt/1309619/novos-aftale-med-teleapotek-ses-som-godt-nyt-aktien-stiger" rel="nofollow ugc">https://proinvestor.com/investornyt/1309619/novos-aftale-med-teleapotek-ses-som-godt-nyt-aktien-stiger</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985345</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985345</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 29 Apr 2025 11:27:00 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 10:47:14 GMT]]></title><description><![CDATA[<p dir="auto">Så er det pludselig ikke sygekasserne, der bestemmer prisen.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985344</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985344</guid><dc:creator><![CDATA[bikube]]></dc:creator><pubDate>Tue, 29 Apr 2025 10:47:14 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 10:30:42 GMT]]></title><description><![CDATA[<p dir="auto">Novo indgår aftale med amerikansk kopi-plageånd <a href="https://proinvestor.com/investornyt/1309581/novo-indgar-aftale-med-amerikansk-kopi-plageand" rel="nofollow ugc">https://proinvestor.com/investornyt/1309581/novo-indgar-aftale-med-amerikansk-kopi-plageand</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985341</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985341</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 29 Apr 2025 10:30:42 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 10:27:22 GMT]]></title><description><![CDATA[<p dir="auto"><a class="plugin-mentions-user plugin-mentions-a" href="/forum/user/anders" aria-label="Profile: anders">@<bdi>anders</bdi></a> og <a class="plugin-mentions-user plugin-mentions-a" href="/forum/user/craw" aria-label="Profile: Craw">@<bdi>Craw</bdi></a> lad os håbe det giver den noget optur</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985338</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985338</guid><dc:creator><![CDATA[Svingtraderen]]></dc:creator><pubDate>Tue, 29 Apr 2025 10:27:22 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 10:18:40 GMT]]></title><description><![CDATA[<p dir="auto">Lidt utraditionelt, men potentielt også ret smart. Det bliver interessant at følge.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985350</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985350</guid><dc:creator><![CDATA[Craw]]></dc:creator><pubDate>Tue, 29 Apr 2025 10:18:40 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 10:16:02 GMT]]></title><description><![CDATA[<p dir="auto">Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims &amp; Hers shares rocket 40%</p>
<p dir="auto"><div class="card col-md-9 col-lg-6 position-relative link-preview p-0">

<div class="card-body">
<h5 class="card-title">
<a class="text-decoration-none" href="https://www.cnbc.com/2025/04/29/novo-nordisk-wegovy-telehealth.html">
Access Denied
</a>
</h5>
<p class="card-text line-clamp-3"></p>
</div>
<a href="https://www.cnbc.com/2025/04/29/novo-nordisk-wegovy-telehealth.html" class="card-footer text-body-secondary small d-flex gap-2 align-items-center lh-2">



<img src="https://www.cnbc.com/favicon.ico" alt="favicon" class="not-responsive overflow-hiddden" style="max-width: 21px; max-height: 21px;" onerror="this.remove()"/>



<p class="d-inline-block text-truncate mb-0"> <span class="text-secondary">(www.cnbc.com)</span></p>
</a>
</div></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985336</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985336</guid><dc:creator><![CDATA[bb8]]></dc:creator><pubDate>Tue, 29 Apr 2025 10:16:02 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 10:11:08 GMT]]></title><description><![CDATA[<p dir="auto">Svingtraderen 13:38 Spændende samarbejde. Interessant at se om det kan være med til at skabe mere interesse for novo blandt de amerikanske investorer.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985334</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985334</guid><dc:creator><![CDATA[Anders_]]></dc:creator><pubDate>Tue, 29 Apr 2025 10:11:08 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 09:46:18 GMT]]></title><description><![CDATA[<p dir="auto">Novo Nordisk har indgået en aftale med sin amerikanske plageånd Hims &amp; Hers, der lever af at producere kopier af patentbeskyttet medicin - herunder Novos fedmemidler Wegovy og Ozempic.<br />
Ifølge Bloomberg News vil Hims &amp; Hers nu begynde at sælge netop Wegovy og Ozempic til sine kunder i stedet for kopier af de to lægemidler.<br />
Hims &amp; Hers har med loven på sin side kunnet kopiere Wegovy og Ozempic, så længe der har været mangel på semaglutid, som er aktivstoffet i de to midler.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985339</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985339</guid><dc:creator><![CDATA[Svingtraderen]]></dc:creator><pubDate>Tue, 29 Apr 2025 09:46:18 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 09:38:28 GMT]]></title><description><![CDATA[<p dir="auto">****NOVO I SAMARBEJDE MED HIMS OM ONLINESALG AF WEGOVY</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985333</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985333</guid><dc:creator><![CDATA[Svingtraderen]]></dc:creator><pubDate>Tue, 29 Apr 2025 09:38:28 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 08:24:44 GMT]]></title><description><![CDATA[<p dir="auto">Novo Nordisk's obesity drug Wegovy debuts in Thailand<br />
By Panu Wongcha-um<br />
April 28, 2025</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985340</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985340</guid><dc:creator><![CDATA[Jan_H]]></dc:creator><pubDate>Tue, 29 Apr 2025 08:24:44 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 07:55:26 GMT]]></title><description><![CDATA[<p dir="auto"><div class="card col-md-9 col-lg-6 position-relative link-preview p-0">

<div class="card-body">
<h5 class="card-title">
<a class="text-decoration-none" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-obesity-drug-wegovy-debuts-thailand-2025-04-28/">
reuters.com
</a>
</h5>
<p class="card-text line-clamp-3"></p>
</div>
<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-obesity-drug-wegovy-debuts-thailand-2025-04-28/" class="card-footer text-body-secondary small d-flex gap-2 align-items-center lh-2">



<img src="https://www.reuters.com/favicon.ico" alt="favicon" class="not-responsive overflow-hiddden" style="max-width: 21px; max-height: 21px;" onerror="this.remove()"/>



<p class="d-inline-block text-truncate mb-0"> <span class="text-secondary">(www.reuters.com)</span></p>
</a>
</div></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985331</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985331</guid><dc:creator><![CDATA[Jan_H]]></dc:creator><pubDate>Tue, 29 Apr 2025 07:55:26 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 03:49:32 GMT]]></title><description><![CDATA[<p dir="auto">"Forsøgsresultater, og især mange af dem, er vigtige argumenter for salget af lægemidler, og senest har det danske selskab med sin mulige pille vist, at risikoen for hjerte-kar-sygdomme nedsættes med 14 pct. Eli Lilly er ikke så langt med sin pille, Orforglipron, men vil komme med data fra syv studier i 2025."</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985330</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985330</guid><dc:creator><![CDATA[JKY_VH]]></dc:creator><pubDate>Tue, 29 Apr 2025 03:49:32 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 03:48:17 GMT]]></title><description><![CDATA[<p dir="auto">Dvsl B.Andersen og artiklen refereres ogaå nu af MW bl.a.. "- Der er jo rigtig, rigtig mange patienter, der er undersøgt med Semaglutid. Det er det mest undersøgte peptid, vi har til obesity og diabetesbehandling, siger den toneangivende diabeteslæge Tina Vilsbøll "</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985337</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985337</guid><dc:creator><![CDATA[JKY_VH]]></dc:creator><pubDate>Tue, 29 Apr 2025 03:48:17 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 02:29:05 GMT]]></title><description><![CDATA[<p dir="auto">Tak Bent. Vi er altid i førertrøjen her på PI. <img src="https://dev.proinvestor.com/forum/assets/plugins/nodebb-plugin-emoji/emoji/android/1f609.png?v=ace6278a214" class="not-responsive emoji emoji-android emoji--wink" style="height:23px;width:auto;vertical-align:middle" title=";-)" alt="😉" /></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985335</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985335</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Tue, 29 Apr 2025 02:29:05 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Tue, 29 Apr 2025 02:25:15 GMT]]></title><description><![CDATA[<p dir="auto">Godmorgen <img src="https://dev.proinvestor.com/forum/assets/plugins/nodebb-plugin-emoji/emoji/android/1f642.png?v=ace6278a214" class="not-responsive emoji emoji-android emoji--slightly_smiling_face" style="height:23px;width:auto;vertical-align:middle" title=":-)" alt="🙂" /></p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985328</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985328</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Tue, 29 Apr 2025 02:25:15 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Mon, 28 Apr 2025 15:52:57 GMT]]></title><description><![CDATA[<p dir="auto">orforglipron (beklager tyrkfejlene) .</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985332</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985332</guid><dc:creator><![CDATA[B.Andersen]]></dc:creator><pubDate>Mon, 28 Apr 2025 15:52:57 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Mon, 28 Apr 2025 15:51:10 GMT]]></title><description><![CDATA[<p dir="auto">Korrektion: "Det er formentligt årsagen til at aktiemarkedet regner for at være et langt bedre produkt”.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985327</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985327</guid><dc:creator><![CDATA[B.Andersen]]></dc:creator><pubDate>Mon, 28 Apr 2025 15:51:10 GMT</pubDate></item><item><title><![CDATA[Reply to NOVO — April 2025 on Mon, 28 Apr 2025 15:48:49 GMT]]></title><description><![CDATA[<p dir="auto">Patienter skal faste, inden de tager Novo Wegovy-tablet. Det skal man ikke med Eli Lillys tablet. Det opfatter Helge ikke som et problem. Rigtig meget andet medicin skal tage på tom mave. Det tror derimod den amerikansk medicinalanalytiker Jared Holz fra storbanken Mizuho er en stor ulempe i forhold til Eli Lillys produkt. "Det er formentligt årsagen til orforglipron for at være et langt bedre produkt” .</p>
]]></description><link>https://dev.proinvestor.com/forum/post/7985329</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/7985329</guid><dc:creator><![CDATA[B.Andersen]]></dc:creator><pubDate>Mon, 28 Apr 2025 15:48:49 GMT</pubDate></item></channel></rss>